Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the first quarter of 2024. Core earnings (excluding one-time charges) of $1.80 per share beat the Zacks Consensus Estimate of$1.73 and were up from $1.54 a year ago. The year-over-year growth was driven by an increase in sales.Revenues of$11.8 billion climbed 10% from the year-ago quarter. On a constant currency basis, sales increased 11%, driven by momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. Sales e ...